Stable protein solution formulation containing high concentration of an anti-VEGF antibody

C:\Interwo n\NRPortbl\DCC\DAR\18137008_l.docx-4/12/2018 The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for d...

Full description

Saved in:
Bibliographic Details
Main Authors Boring, Charles, Wan, Li, Kulshreshtha, Alok, Alani, Laman, Zeng, Yuhong, Zhang, Huixiang
Format Patent
LanguageEnglish
Published 09.07.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:C:\Interwo n\NRPortbl\DCC\DAR\18137008_l.docx-4/12/2018 The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.
Bibliography:Application Number: AU20180274882